This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Utah Medical Products, Inc. Reports Financial Performance For Fourth Quarter And Year 2010

SALT LAKE CITY, Jan. 27, 2011 (GLOBE NEWSWIRE) -- In the fourth calendar quarter (4Q) 2010 and year of 2010, Utah Medical Products, Inc.'s (Nasdaq:UTMD) changes in financial results compared to the same time period in the prior calendar year were as follows:
  4Q  (October – December) Year (January – December)
Sales: ( 4%) ( 3%)
Gross Profit: ( 5%) ( 4%)
Operating Income: ( 8%) ( 5%)
Net Income: ( 2%) ( 4%)
Earnings Per Share: ( 2%) ( 4%)

Profitability measures compared to the same time periods in the prior calendar year were as follows:
  4Q10 4Q09 2010 2009
Gross Profit Margin (GPM): 52.9% 53.2% 52.6% 53.2%
Operating Profit Margin (OPM): 35.1% 36.6% 35.5% 36.4%
Net Profit Margin (NPM): 24.3% 23.8% 23.9% 24.1%

According to CEO Kevin Cornwell,

"Despite the decline of sales and eps in 2010, UTMD's profitability demonstrated continued excellent overall performance. Domestic sales declined as U.S. hospitals have reduced utilization of physician-preference specialty devices. UTMD's sales growth came in areas where it has its lowest profit margins, primarily internationally where UTMD sells through third party distributors. The expansion of facilities in Utah and the consolidation of Oregon operations into Utah were completed in 2010. The full benefit of the consolidation will not be realized until 2011.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
FB $100.81 -0.19%
GOOG $678.90 -0.76%
TSLA $161.70 13.00%
YHOO $26.81 -1.10%
AAPL $94.19 -0.08%


Chart of I:DJI
DOW 15,725.76 -188.98 -1.19%
S&P 500 1,827.93 -23.93 -1.29%
NASDAQ 4,243.1530 -40.4390 -0.94%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs